以下文章来源于果壳 ，作者黎小球 果壳 . 科学和技术，是我们和这个世界对话所用的语言。 幽门螺旋杆菌，生活方式， 都与胃癌发生有关。 文 ｜ 黎小球 编辑 ｜ odette 来源｜ 果壳（ID：Guokr42） 封面来源 ｜ unsplash 目前全球有80亿人口，中国14亿。然而就是这不到20%占比的中国人，却背负了全世界约40%的胃癌病例。更严峻的是，大多数胃癌患者被确诊时，疾病已 步入进展期，错过了早期治疗机会。 这并非偶然的概率问题。胃癌是一种多因素影响、多发展阶段的疾病，高发背后的原因自然也很复杂。 但在中国人的胃癌风险版图里，有一个最大的推 手，近七成的胃癌要归因于它。 那是一种细菌，此时此刻，它正存活在一半中国人的体内。 约40%的胃癌，发生在中国 胃癌，是原发于胃部的恶性肿瘤。虽然不同年份有波动， 但在全球癌症谱上，胃癌的发病率与死亡率一直位列前五。 根据国际癌症研究机构（IARC）的数据，2022年全球新增胃癌病例约97万例，仅次于肺癌、乳腺癌、结直肠癌、前列腺癌，位列第5；死亡约66万例，仅次 于肺癌、结直肠癌、肝癌、乳腺癌，同样位列第5。 2022年，胃癌的发病和死亡位居全球癌症榜第五 ...

Core Viewpoint - The article emphasizes the importance of awareness and early detection of gastric cancer, highlighting its common causes and the need for preventive measures and regular screenings to improve public health. Summary by Sections Gastric Cancer Evolution - Gastric cancer progresses through five stages: chronic superficial gastritis, chronic atrophic gastritis, intestinal metaplasia, dysplasia, and finally gastric cancer [4][5]. Early Symptoms and Warning Signs - Early symptoms of gastric cancer are often subtle and can be confused with common gastric issues, but may include persistent upper abdominal pain, appetite loss, unexplained weight loss, and gastrointestinal bleeding [7][8]. High-Risk Groups for Gastric Cancer - Individuals aged 45 and above, especially those with a history of chronic gastritis, gastric ulcers, or family history of gastric cancer, are considered high-risk and should undergo regular screenings [8][9]. Early Screening Methods - Recommended screening methods include blood tests for anemia, stool tests for occult blood, tumor marker tests, and gastroscopy for individuals over 40 every two years [10]. Preventive Measures - Key preventive strategies include eradicating Helicobacter pylori, improving dietary habits, avoiding high-salt foods, and maintaining a healthy lifestyle to reduce the risk of gastric cancer [11][13][14].

Core Viewpoint - MIRXES-B (02629.HK) has received approval from the National Medical Products Administration of China for its core product GASTROClear™, marking it as the first blood test approved for non-invasive gastric cancer screening in China [1] Product Approval - GASTROClear™ is the world's first microRNA blood test approved for early detection of gastric cancer, assessing cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] - The product was previously approved in Singapore in 2019 and received "breakthrough device" designation from the FDA in 2023 [1] Significance of Approval - The approval in China represents a significant milestone for the company, indicating a successful transition from research and development to commercialization [1] - This achievement reflects the company's long-term commitment and investment in technological innovation and large-scale clinical trials [1]

Core Insights - MIRXES-B's core product GASTROClear has received approval from the National Medical Products Administration of China for use as a non-invasive gastric cancer screening IVD product, marking a significant milestone in the company's journey from research and development to commercialization [1] - GASTROClear is the first blood test approved for gastric cancer screening in China, utilizing a microRNA-based method to assess gastric cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] Group 1 - GASTROClear is designated for screening high-risk adults aged 45-74 as defined by the "Guidelines for Screening and Early Diagnosis and Treatment of Gastric Cancer in China (2024 Edition)," potentially covering over 500 million individuals [2] - The product will be implemented in both public and private medical institutions in China as an IVD testing project, significantly expanding the company's business space in the gastric cancer screening market [2] Group 2 - The company plans to continue increasing its commercialization efforts in China, including expanding the sales team and upgrading local production capabilities [2] - There will be a focus on strengthening business development and collaboration in mainland China to promote broader adoption of the product [2]

Core Insights - MIRXES-B (02629) has received approval from the National Medical Products Administration of China for its core product GASTROClear, marking it as the first blood test approved for non-invasive gastric cancer screening in China [1] - GASTROClear is the world's first microRNA blood test approved for early detection of gastric cancer, assessing cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] - The product is expected to cover a potential population of over 500 million high-risk adults aged 45-74, as defined by the "Guidelines for Gastric Cancer Screening and Early Diagnosis and Treatment (2024 Edition)" [1] Company Strategy - The company plans to continue expanding its commercialization efforts in China, including increasing the size of its sales team and upgrading local production capabilities [2] - The company aims to strengthen its business development and collaboration efforts in mainland China to promote wider adoption of its products [2]

Core Insights - MIRXES-B's core product GASTROClear™ has received approval from the National Medical Products Administration of China for Class III medical device registration, marking it as the first blood test approved for non-invasive gastric cancer screening in China [1] - GASTROClear™ is the world's first microRNA blood test approved for early detection of gastric cancer, assessing cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] - The approval allows GASTROClear™ to be used for screening high-risk adults aged 45-74, potentially covering over 500 million people in China [1] Company Strategy - The company plans to continue expanding its commercialization efforts in China, including increasing the size of its sales team and upgrading local production capabilities [2] - The company aims to strengthen its business development and collaboration efforts in mainland China to promote wider adoption of its products [2]

Core Insights - Gastric cancer is often diagnosed at an advanced stage, with early symptoms resembling common stomach ailments, leading to a significant drop in the five-year survival rate to 30% [1] - Early diagnosis is challenging due to the discomfort associated with gastroscopy, which is often perceived as a daunting procedure, and long waiting times discourage many individuals from pursuing screening [1] Industry Challenges - The difficulty in early detection of gastric cancer is primarily attributed to the similarity of early symptoms to less severe stomach issues, resulting in delayed diagnosis [1] - The perception of gastroscopy as a "sword-swallowing" level challenge contributes to the reluctance of individuals to undergo necessary screening [1] - Long waiting times for screening procedures further exacerbate the issue, leading to a high rate of abandonment among potential patients [1]

Core Viewpoint - The introduction of the world's first AI model for gastric cancer screening, DAMO GRAPE, represents a significant advancement in early detection and intervention, potentially increasing the five-year survival rate from 35% to over 90% if cancer is detected early [3][5]. Group 1: AI Model Development and Application - The DAMO GRAPE model utilizes plain CT imaging to identify early gastric cancer lesions and has undergone large-scale clinical research involving nearly 100,000 individuals across 20 centers [3]. - The model's initial screening significantly reduces the high-risk population for gastric cancer, achieving detection rates of 24.5% and 17.7% in two regional hospitals, with approximately 40% of detected cases being asymptomatic [4]. - The AI model demonstrates a sensitivity of 85.1% and specificity of 96.8%, surpassing radiologist diagnoses by 21.8% and 14.0%, respectively, making early detection of gastric cancer via plain CT feasible [4]. Group 2: Clinical Impact and Future Plans - The AI model has shown the ability to detect gastric cancer 2 to 10 months earlier than traditional methods, as evidenced by a case where a patient was diagnosed with advanced gastric cancer that could have been identified earlier with AI monitoring [4]. - The model is being deployed in high-incidence areas for gastric cancer across the country, with plans for large-scale promotion both domestically and internationally [5].